The latest price target for iSpecimen (NASDAQ:ISPC) was reported by EF Hutton on September 23, 2022. The analyst firm set a price target for $4.25 expecting ISPC to rise to within 12 months (a possible 1306.82% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for iSpecimen (NASDAQ:ISPC) was provided by EF Hutton, and iSpecimen maintained their buy rating.

There is no last upgrade for iSpecimen

There is no last downgrade for iSpecimen.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iSpecimen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iSpecimen was filed on September 23, 2022 so you should expect the next rating to be made available sometime around September 23, 2023.

While ratings are subjective and will change, the latest iSpecimen (ISPC) rating was a maintained with a price target of $5.50 to $4.25. The current price iSpecimen (ISPC) is trading at is $0.30, which is out of the analyst’s predicted range.